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Context: Calcitonin (CT) is a sensitivemarker ofmedullary thyroid carcinoma (MTC) and is used for
primary diagnosis and follow-up after thyroidectomy. However, persistently elevated CT is ob-
served even after complete surgical removal without evidence of a recurrent or persistent tumor.
Objective: To investigate the presence of assay interference in the serum CT of MTC patients who
are apparently without a structural disease.
Patients andMethods:We studied three indexMTC cases for CT assay interference and 14 patients
with metastatic MTC. The CT level was measured using an immunofluorometric assay. Screening
for assay interference was performed by determination of CT levels before and after serum treat-
ment with polyethylene glycol. Additionally, samples were analyzed by chromatography on ultra-
performance liquid chromatography and protein A-Sepharose.
Results: Patients with biochemical and structural disease showed CTmean recovery of 84.1% after
polyethylene glycol treatment, whereas patients suspected of interference showed recovery from
2–7%. The elution profile on UPLC showed that the immunometric CT from these three patients
behaved like a highmolecularmass aggregate (300 kDa). Additionally,when these sampleswere
applied to theproteinA-Sepharose, CT immunoreactivitywas retainedon the columnandwasonly
released after lowering the pH.
Conclusions: For the first time, our results show the presence of a novel pitfall in the CT immu-
noassay: “macrocalcitonin.” Its etiology, frequency, and meaning remain to be defined, but its
recognition is of interest and can help clinicians avoid unnecessary diagnostic investigations and
treatment during the follow-up of MTC. (J Clin Endocrinol Metab 101: 653–658, 2016)
Measurement of serum calcitonin (CT) is a majormarker of medullary thyroid carcinoma (MTC)
used for the primary diagnosis and to predict the outcome
(1), and it can also be used as an aid in planning long-term
follow-up after thyroidectomy (2, 3). Additionally, in
RET mutation carriers, who are at elevated risk for mul-
tiple endocrine neoplasia 2, both basal and stimulated se-
rum CT could also help to guide the timing of thyroidec-
tomy and indicate the need for a more extensive initial
surgical approach (3). However, such strategies remain
controversial (4), especially regarding the limitations of
assay methods and the interpretation of results.
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Indeed, persistently elevated CT can be observed even
after complete surgery with no evidence of a persistent or
recurrent tumor in the follow-up, leading to potentialmis-
diagnosis. Despite recent improvements in the immuno-
chemiluminometric CT assays that minimize cross-reac-
tivity with procalcitonin and CT-related peptides, some
challenges remain, especially concerning the presence of
heterophilic antibodies in patient serum, which can pro-
duce elevated CT (5–8).
Thus, some challenges arise in clinical practice. When
the postoperative serum CT is undetectable, the risk of
persistent or recurrent residual disease is low, and further
CT-stimulating tests or imaging techniques are not imme-
diately required. In contrast, if CT levels exceed 500 pg/
mL, radiographically identifiable distant metastases are
almost always present (9). However, upon modestly in-
creased CT levels (150 pg/mL), the presence of local or
distant metastasis by radiographic imaging is difficult to
detect and requires additional and often expensive tests
during follow-up (10). An additional challenge occurs
when CT levels are persistently increased but unchanged
over time.
Here, we describe three patients withMTCwhose serum
CT in the late postoperative period was modestly increased
but showed no evidence of residual tumor. They were diag-
nosed as having a new interference in the CT immunoassay,
which was characterized by falsely increased values and
herein termed “macrocalcitonin” (macro-CT).
Patients and Methods
We studied three indexMTC cases suspected of havingCT assay
interference (A, B, and C) and, for comparison, 14 patients with
MTC who were followed at the Division of Endocrinology, De-
partment ofMedicine, Escola Paulista deMedicina, Federal Uni-
versity of São Paulo, São Paulo, Brazil. The study was approved
by the Ethical Committee of Universidade Federal de São Paulo/
Escola Paulista de Medicina (CAAE: 12820313.4.0000.5505),
and written informed consent was obtained from each subject.
Patient A
In 2003, a 45-year-old white woman attended with a history
ofmultinodular goiter. Cytologywas benign, but the patientwas
submitted to total thyroidectomydue to recent increased volume
of the thyroid gland. Histopathology showed an isolated MTC
(2.0 cm) with no evidence of capsular, vascular, or extrathyroi-
dal invasion. During the postoperative period, serum CT and
cervical ultrasound were unremarkable. In April 2010, the pa-
tient was referred to us for further evaluation. Revision of his-
topathology confirmed the diagnosis ofMTC. The presence of a
genomic mutation in the geneRETwas negative. There were no
suspect lymph nodes on cervical ultrasound, and her first bio-
chemical analysis showed a slightly increased serum CT (118
pg/mL). Further biochemical analyzes showed a serumCT rang-
ing from 138–262 pg/mL. Carcinoembryonic antigen measure-
ments were all normal. Neck and thorax tomography, abdomen
and pelvis magnetic resonance imaging, and a bone scan showed
no abnormalities. During 3 years of follow-up, the patient re-
mained very well with no clinical or imaging evidence of a re-
sidual or recurrent tumor, but she maintains persistently in-
creased serum CT levels.
Patient B
In 2011, a 16-year-old boy carrying the V804M RET muta-
tion was referred for evaluation. Physical examination and cer-
vical ultrasoundwere normal. BasalCTwasmildly increased (35
pg/mL). A pentagastrin stimulation test was performed and
showed a blunted response (28.4, 35.0, 37.0, 30.0, and 25.7
pg/mL at 0, 2, 5, 10, and 15 min, respectively). Screening for
hyperparathyroidism and pheochromocytoma was negative.
Despite the low risk of American Thyroid AssociationGuideline
Task Force (ATA) (10) stratification at the time (ATA risk level
A), the patient and his family were selected for prophylactic
thyroidectomy. He underwent surgery in May 2011, and histo-
pathology was normal, including the absence of C-cell hyper-
plasia. During 3 years of follow-up, the patient maintained nor-
mal cervical ultrasound but had persistently increased serumCT
(30–40 pg/mL).
Patient C
A 40-year-old woman carrier of the E768D RET mutation
was referred to us in 2010 for evaluation. She had already been
submitted to prophylactic thyroidectomy in January 2010, and
histopathology revealed a 0.6-cm diameter MTC and bilateral
C-cell hyperplasia. Postoperative cervical ultrasound was com-
pletely normalwith no evidence ofmass or suspect lymph nodes.
Screening for hyperparathyroidism and pheochromocytoma
was negative. The first serumCT showed a value of 40.3 pg/mL.
Serum carcinoembryonic antigen was within the normal range.
After 3 years of follow-up, there has been no evidence of clinical
or imaging recurrence of MTC, but the patient’s CT serum re-
mains moderately increased (35–50 pg/mL).
CT measurement and polyethylene glycol (PEG)
treatment
Serum CT levels were measured by an in-house two-site im-
munofluorometric assay using two mouse monoclonal antibod-
ies against two different epitopes of CT. This assay has an ana-
lytical sensitivity of 1.0 pg/mL, and the 95% reference values are
5.5 and 11.1 pg/mL for females and males, respectively (11). In
thyroidectomized patients who have been treated for differenti-
ated thyroid carcinoma,more than97.5%hadaCT6.9pg/mL
(11). Screening for assay interference was carried out by the
determination of CT levels before and after treating the serum
with PEG (PEG-6000; Labsynth Products Labs Ltd). The PEG
protocolwasperformedas previously described (12, 13). Briefly,
250 L of 250 g/L PEG-6000 solution was added to 250 L of
each serum sample, vortex mixed for 1 minute, and centrifuged
at 9500  g for 5 minutes at 25°C; the CT level was measured
in the supernatant in triplicate. Recovery (percentage) was cal-
culated by the original CT value. We also analyzed the linearity
of serum CT measurements after serial dilution with an equal
amount of mouse serum to check the possible interference of
heterophilic antibodies. Suspect sampleCTwas also analyzed by
a commercially available electrochemiluminescence immunoas-
say (Elecsys Calcitonin; Roche Diagnostics).
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Gel filtration on ultra-performance liquid
chromatography
The three serum samples suspected of interference—a sample
obtained from the washout from a fine-needle aspiration of a
metastatic MTC lymph node and two serum samples from pa-
tients with metastatic disease—were analyzed by gel filtration
chromatography. For this analysis, samples were chromato-
graphedon aBiosep S-3000 column306.7mm(Phenomenex)
coupled to an ultra-performance liquid chromatography system
(AKTA;GEHealthcare). After calibrating the columnwith stan-
dard molecular weights (GE Healthcare), serum samples (200
L) were applied and eluted with a 0.05 M PBS at pH 7.4 and a
flow rate of 0.5 mL/min. Aliquots of 0.5 mL were collected sep-
arately for CT measurement.
Affinity chromatography on protein A-Sepharose
Possible interferences were also characterized on protein A-
Sepharose CL-4B (GE Healthcare), which specifically binds Ig.
Initially, 2 mL of protein A-Sepharose was packed into a plastic
column and equilibrated in PBS. Serum sample (0.5 mL) and the
same volume of standard CT (WHO International Reference
Standard for Human Calcitonin 89/620, National Institute for
Biological Standards andControl)were applied separately to the
columnand elutedwithPBS; then, 0.5-mLaliquots (n10)were
collected for subsequent CTmeasurement. After this procedure,
the column was washed 10 times with PBS, followed by the
addition of 5 mL of 0.1 M glycine at pH 2.8. Finally, 0.5-mL
aliquots (n  10) were collected, and each was assayed for CT.
Thyroglobulin autoantibodies, thyroperoxidase
autoantibodies, and procalcitonin measurement
In the serum samples suspected for interference, we per-
formed thyroglobulin autoantibody and thyroperoxidase auto-
antibody assays using electrochemiluminescence immunoassay
(Roche Diagnostics) and procalcitonin measurement by an
ELISA (USCN Life Science Inc).
Results
Patientswithbiochemical and structural disease presented
a CT mean recovery of 84.1% (ranging from 51–135%)
after PEG treatment (Table 1). Interestingly, the three sus-
pect patients for interference showed very low CT recov-
ery, ranging from 2–7%. In comparisonwith the in-house
assay, serum levels of CT determined by commercial
method showed lower values of 67, 2, and 4 pg/mL for
cases A, B, and C, respectively.
Analyzes by gel filtration on a Biosep S-3000 column
showed that CT obtained from washout of fine-needle
aspiration of a metastatic MTC lymph node (Figure 1A)
had an immunometric CT elution profile between 20 and
23 minutes, which corresponds to peptides of low molec-
ular weight. As expected, the two serum samples from
patients with metastatic MTC (patients 10 and 11)
showed a similar retention time for immunometric CT
when compared with the CTwashout sample (Figure 1, B
andC). Surprisingly, the patientwith low recovery (Figure
1D) had almost all immunometric CT eluted as a high
molecular mass aggregate (300 kDa).
Figure 2 shows the elution profiles of CT that did and did
not bind protein A-Sepharose. As expected, standard CT
(Figure 2A) and serum from patients with metastatic MTC
(Figure2,BandC) showed immunoreactivity forCT inearly
elution steps, confirming that CT was not retained in the
column. However, when samples suspected of assay inter-
ference were applied to the protein A-Sepharose, CT immu-
noreactivity was almost completely retained on the column
andwasonly releasedafter theadditionof0.1Mglycine-HCl
(Figure 2, D–F), clearly indicating an Ig-CT complex.
Table 1. Clinical and Laboratory Data of Patients With MTC Enrolled in the CT Immunoassay Interference Study
Patient
ID Gender Age, y
RET
Mutation
Years Since
Thyroidectomy
Disease
Status
CT,
pg/mL
CT-PEG,
pg/mL
Recovery,
%
A F 66 Negative 12 B 261 9 3.4
B F 40 E761D 4 B 36 0.6 1.7
C M 16 V804M 4 B 38 2.8 7.4
1 F 22 C634Y 2 B/S 21 754 18 567 85.3
2 F 28 Negative 5 B/S 19 800 18 729 94.6
3 M 48 Negative 9 B/S 14 070 12 985 92.3
4 M 35 Negative 9 B/S 11 795 7928 67.2
5 M 62 Negative 9 B/S 11 271 7642 67.8
6 F 44 S891A 4 B/S 10 087 7644 75.8
7 F 46 C634Y 1 B/S 9193 5414 58.9
8 F 44 Negative 7 B/S 941 848 90.1
9 F 67 Negative 14 B/S 744 593 79.7
10 F 57 S891A 4 B/S 429 438 102.1
11 F 22 C634Y 6 B/S 249 338 135.7
12 M 57 S891A NP B/S 114 59 51.7
13 M 41 C634Y 3 B/S 87 78 89.7
14 F 39 Negative 6 B/S 57 49 86.0
Abbreviations: F, female; M, male; NP, not performed; B, presenting only biochemical disease; B/S, presenting biochemical and structural disease.
Blood serum from patients A, B, and C was suspected for CT immunofluorometric assay interference. RET mutation indicates identified germ line
RET mutation. CT was measured by the in-house assay. CT-PEG and CT were measured after PEG treatment.
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Sera from the three reported cases were negative for
thyroglobulin autoantibody, thyroperoxidase autoanti-
body, and procalcitonin.
Discussion
To our knowledge, the present study demonstrates for the
first time the presence of a new interference in the serum
CT immunoassay, herein termed macro-CT. This new in-
terference results in a falsely increased CT measurement
and represents a new challenge for MTC management.
CT is recognized as the cornerstone for the manage-
ment ofMTC. Screening forMTC in nodular thyroid dis-
ease using serum CT measurements has identified this tu-
mor in 0.3–1.5% of cases (4, 10). In this setting, some
authors argue for CT serum testing in the context of thy-
roid nodule evaluation to allow for the early diagnosis of
Figure 1. Representative elution profiles of immunometric serum calcitonin (CT) observed through ultra-performance liquid chromatography.
Elution distribution from a sample obtained from the washout of fine-needle aspiration of a metastatic MTC lymph node (A) and serum from
patients with high (B and C) and low (D) CT recovery after PEG treatment. Sera samples were chromatographed on a Biosep S-3000 column 30 
6.7 mm (Phenomenex) coupled to an ultra-performance liquid chromatographer.
Figure 2. Calcitonin (CT) immunoreactivity after elution via protein A-Sepharose affinity chromatography. WHO International Reference Standard
for Human Calcitonin 89/620, National Institute for Biological Standards and Control (A), serum from patients with metastatic MTC (B and C), and
patients with MTC carrying interference in CT assay (D–F) obtained through the column and the elution on protein A-Sepharose.
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a potentially more aggressive tumor (1, 14, 15) and to
improve the sensitivity of fine-needle aspiration cytology,
which will actually confirm the diagnosis of MTC in less
than 50% of patients (16). However, this issue is contro-
versial, and many questions remain unanswered, espe-
cially regarding cost effectiveness, the availability of
pentagastrin for stimulation testing, and the difficult in-
terpretation of false-positive serumCT levels (3, 4). In this
regard, when evaluating preoperative thyroid nodules
with serum CT determination, clinicians should be aware
that variable elevations in CT levels may also underlie
several clinical conditions, such as autoimmune thyroid-
itis, chronic renal failure, hypergastrinemia, hyperpara-
thyroidism, and inflammatory diseases and numerous tu-
mors, especially those derived fromneuroendocrine tissue
from the intestine and lungs (3, 17). Depending on the
immunoassay performed, approximately 10% of normal
subjects might have CT levels greater than 10 pg/mL (3).
Additionally, the serum CT level varies according to age,
sex, physical activity, and the use of common drugs such
as proton pumpblockers, beta blockers, and calcium (17).
During the follow-up of thyroidectomized patients for
MTC, certain concerns remain because interference in the
CT immunoassay cannot be avoided entirely (3).
Thus, despite the high reliability and sensitivity of the
new immunochemiluminometric CT measurement (18,
19), some concerns persist, especially regarding the pres-
ence of falsely elevated serum CT levels. With these new
immunoassays, cross-reactivity with procalcitonin and
other related peptides has been almost completely abol-
ished, but the presence of heterophilic antibodies resulting
in falsely increased levels is not negligible and occurs in up
to 3.7% of cases (20).
In the present study, sera from the three reported cases
were negative for antithyroid antibodies and procalci-
tonin. Furthermore, the presence of heterophilic antibod-
ies was also excluded once the CT results maintained lin-
earity after dilution; this interference was also prevented
by adding an excess ofmouse serumduring the routineCT
immunometric assay.
Another possibility for the unexpectedly high level of
CT in these three reported cases could be the presence of
antibodies against CT in the sera. In fact, the interference
of endogenous antibodies during routine immunoassays
has alreadybeendescribed for someproteins andpeptides,
especially for prolactin, insulin, GH, LH, and TSH (21–
23), but thus far not for CT. The nature of this phenom-
enon involves the formation of macroaggregates between
the peptide and Ig, mainly IgG, but other molecular mod-
ifications, including glycosylation and covalent/noncova-
lent binding, are also possible (24). Our findings showed
a similar mechanism as demonstrated by three strategies:
demonstration of low recovery after PEG treatment, the
presence of immunoreactivity for CT as amacroaggregate
in the gel filtration chromatography, and the presence of
CT-Ig complexes by protein A-Sepharose analysis. How-
ever, some caremay be neededwhen finding unexpectedly
high levels of CT. The macro-CT phenomenon may be
patient sample- and assay system-dependent. An example
of this was the discrepancy observed between serum CT
values obtained by the in-house method compared with
the commercial test. These disagreements have also been
observed in the description of other autoimmune macro-
aggregate phenomena, such as for macroprolactin (25–
27),macro-TSH(21,28), andmacro-FSH(23).Therefore,
it is possible that the same phenomenon is occurring with
macro-CT. This could occur due to differences in the af-
finity of CT for endogenous anti-CT antibody or the an-
tibodies used by each different CT immunoassay. Another
possibility is that, for different serum samples, there were
anti-CT antibodies directed against different epitopes,
which could also influence CT recognition by a specific
method (27). Therefore, if the endogenous anti-CT anti-
body binds to a specific CT peptide site required for rec-
ognition of an immunoassay, this method will not recog-
nize CT adequately.
Although the exact etiology and frequency of the mac-
ro-CT phenomenon remain to be explored, its discovery
opens new perspectives for refining the management of
patients with MTC. Additional importance for this work
arises if a CT measurement was used in the initial man-
agement of thyroid nodules, as proposed by some authors
(1, 14, 15). In these cases, additional caution must be
taken, especially if the CT measurement was only mod-
erately increased (150 pg/mL). Finally, rather than a
simple immunological artifact, macro-CT recognition is
noteworthy because it can help clinicians avoid unneces-
sarydiagnostic investigations and treatmentsduringMTC
follow-up.
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